Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial by Ma Somsouk (283498)

“…<div><p>The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. …”

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Dose- and time-dependent effect of IFN-γ and TNF-α on benzamil-sensitive <i>I</i>_sc and TEER in HBECs. by Anusree Sasidharan (19226521)

sC5b-9 patients decrease in patients treated with mycophenolate mofetil. by Joshua M. Thurman (517193)

“…When analyzed separately based upon treatment, the decrease in sC5b-9 levels was due to a decrease in patients treated with mycophenolate mofetil (P < 0.001 by linear regression; n = 12 for all time-points). …”

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Purified serum IgG from SPMS patients decreased the amount of claudin-5 protein, and IgG from all clinical subtypes of MS patients increased the amount of VCAM-1 protein in TY09 ce... by Fumitaka Shimizu (545145)

“…(G) The amount of VCAM-1 protein in the TY09 cells was significantly increased after exposure to the purified IgG fraction from patinets with all clinical subtypes of MS, whereas it was not changed by the IgG from healthy controls, as determined by a Western blot analysis. (H) The TEER value of the TY09 cells was significantly decreased after exposure to the purified IgG fraction from SPMS patients, although it was not changed by incubation with the purified serum IgG fractions from RRMS-R or RRMS-S patients, or from healthy controls (mean ± SEM, SPMS n = 6, RRMS-R n = 4, RRMS-S n = 6, Normal n = 5). …”

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)